Phil Skolnick
Director/Board Member at Gilgamesh Pharmaceuticals, Inc.
Phil Skolnick active positions
Companies | Position | Start | End |
---|---|---|---|
NYU Langone Medical Center
NYU Langone Medical Center Hospital/Nursing ManagementHealth Services NYU Langone Medical Center is a premier academic medical center in the United States that is committed to excellence in patient care, medical education, and scientific research. The center is based in New York, NY, and has subsidiaries in the United States. The center offers a variety of non-degree educational programs, including the Pharmacy Technician Training Program and the PhD program at Vilcek Institute of Graduate Biomedical Sciences. NYU Langone Health's office of science and research is led by a team that is committed to supporting the excellence of their research enterprise. | Corporate Officer/Principal | 31/12/2000 | - |
Uniformed Services University of the Health Sciences | Corporate Officer/Principal | - | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | Director/Board Member | - | - |
Career history of Phil Skolnick
Former positions of Phil Skolnick
Companies | Position | Start | End |
---|---|---|---|
OPIANT PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/01/2017 | 01/03/2023 |
National Institute on Drug Abuse | Corporate Officer/Principal | 31/12/2009 | 31/01/2017 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Chief Tech/Sci/R&D Officer | 31/12/2000 | 31/12/2008 |
President | 31/12/2006 | 31/12/2008 |
Training of Phil Skolnick
Long Island University | Undergraduate Degree |
George Washington University School of Medicine & Health | Doctorate Degree |
Statistics
International
United States | 9 |
Operational
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
President | 1 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 5 |
---|---|
Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
National Institute on Drug Abuse | Government |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
NYU Langone Medical Center
NYU Langone Medical Center Hospital/Nursing ManagementHealth Services NYU Langone Medical Center is a premier academic medical center in the United States that is committed to excellence in patient care, medical education, and scientific research. The center is based in New York, NY, and has subsidiaries in the United States. The center offers a variety of non-degree educational programs, including the Pharmacy Technician Training Program and the PhD program at Vilcek Institute of Graduate Biomedical Sciences. NYU Langone Health's office of science and research is led by a team that is committed to supporting the excellence of their research enterprise. | Health Services |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Phil Skolnick
- Experience